Acticor Biotech Summary
Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.
Acticor Biotech is a spin-off company from Inserm (French National Institute of Health and Medical Research) founded in November 2013 and located in the Inserm U1148 building inside the Bichat Hospital in Paris.
Acticor Biotech develops a biologic drug candidate based on academic research on a platelet glycoprotein called GPVI. GPVI is a platelet receptor of collagen and polymerized fibrin. The drug candidate ACT017 is a humanized fragment of monoclonal antibody which binds to GPVI and inhibits platelet adhesion and aggregation on collagen and polymerized fibrin. The efficacy and safety of ACT017 have been demonstrated in vitro and in vivo animal models. Acticor Biotech announced, end of January 2018, the completion of its phase I clinical trial in healthy volunteers. The primary endpoint assessing safety and tolerability was achieved with no serious adverse event reported at any of the doses tested. With the results of this study, the company will be able to determine the most appropriate ACT017 dosage for phase II studies which should start Q3 2018.
Partners and awards
Concours Mondial de l’Innovation 2016
Laureate 2016, “Silver Economy” category
Tremplin des Entreprises 2016
Since 2015, this project received the label EIP by Medicen (Innovative Enterprise) and has been recognized by Genopole. In 2016, Acticor Biotech was laureate of the Concours Mondial d’ Innovation (World Innovation Contest) and was also laureate of the Concours Tremplin d’Entreprises du Sénat (national contest for innovative enterprises).
Recently, Acticor Biotech signed a partnership contract with INSERM and received grants from Bpifrance (innovation support).